Neoadjuvant  	Neoadjuvant  	 NNP	B-NP
and  	and  	 CC	O
adjuvant  	adjuvant  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
in  	in  	 IN	O
renal  	renal  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma 	carcinoma 	 NNS	I-NP
:  	:  	 :	O
more  	more  	 JJR	O
questions  	questions  	 NNS	O
than  	than  	 IN	O
answers  	answers  	 NNS	O
The  	The  	 DT	O
current  	current  	 JJ	O
standard  	standard  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
early  	early  	 JJ	O
stage  	stage  	 NN	O
( 	( 	 -LRB-	O
I-III 	I-III 	 NNP	B-NP
)  	)  	 -RRB-	O
renal  	renal  	 JJ	B-NP
cell  	cell  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
RCC 	RCC 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
surgery 	surgery 	 NN	O
.  	.  	 .	O
While  	While  	 IN	O
the  	the  	 DT	O
prognosis  	prognosis  	 NN	O
of  	of  	 IN	O
stage  	stage  	 NN	O
I  	I  	 PRP	O
tumors  	tumors  	 RB	O
is  	is  	 VBZ	O
excellent 	excellent 	 JJ	O
,  	,  	 ,	O
stage  	stage  	 NN	O
II  	II  	 NNP	O
and  	and  	 CC	O
particularly  	particularly  	 RB	O
stage  	stage  	 VB	O
III  	III  	 NNP	O
have  	have  	 VBP	O
a  	a  	 DT	O
high  	high  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
relapse 	relapse 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
adjuvant  	adjuvant  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
RCC  	RCC  	 NNP	B-NP
remains  	remains  	 VBZ	O
an  	an  	 DT	O
area  	area  	 NN	O
of  	of  	 IN	O
investigation 	investigation 	 NN	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
patient  	patient  	 JJ	O
selection  	selection  	 NN	O
being  	being  	 VBG	O
a  	a  	 DT	O
key  	key  	 JJ	B-NP
aspect 	aspect 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
two  	two  	 CD	O
prognostic  	prognostic  	 JJ	B-NP
nomograms  	nomograms  	 NN	I-NP
to  	to  	 TO	O
establish  	establish  	 VB	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
relapse  	relapse  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
resected  	resected  	 JJ	B-NP
RCC 	RCC 	 NNP	I-NP
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
earlier  	earlier  	 JJR	O
studies  	studies  	 NNS	O
of  	of  	 IN	O
adjuvant  	adjuvant  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	B-NP
chemotherapy  	chemotherapy  	 NNS	I-NP
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
immunotherapy  	immunotherapy  	 NN	B-NP
after  	after  	 IN	O
nephrectomy  	nephrectomy  	 NNS	B-NP
have  	have  	 VBP	O
failed  	failed  	 VBN	O
to  	to  	 TO	O
show  	show  	 VB	O
any  	any  	 DT	O
benefit  	benefit  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
outcome  	outcome  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
at  	at  	 IN	O
risk  	risk  	 NN	O
of  	of  	 IN	O
developing  	developing  	 VBG	O
local  	local  	 JJ	O
recurrence  	recurrence  	 NN	O
or  	or  	 CC	O
distant  	distant  	 JJ	O
metastases 	metastases 	 NN	B-NP
.  	.  	 .	O
Two  	Two  	 CD	O
recent  	recent  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trials  	trials  	 NNS	O
with  	with  	 IN	O
vaccines  	vaccines  	 NNS	O
( 	( 	 -LRB-	O
autologous  	autologous  	 JJ	B-NP
tumor  	tumor  	 NN	I-NP
cell  	cell  	 NN	I-NP
vaccine  	vaccine  	 NN	I-NP
and  	and  	 CC	O
autologous  	autologous  	 JJ	B-NP
tumor-derived  	tumor-derived  	 JJ	I-NP
heat  	heat  	 NN	I-NP
shock  	shock  	 NN	I-NP
protein  	protein  	 NN	I-NP
peptide  	peptide  	 VBD	O
complex-96 	complex-96 	 CD	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
shown  	shown  	 VBN	O
promising 	promising 	 JJ	O
,  	,  	 ,	O
albeit  	albeit  	 IN	O
still  	still  	 RB	O
preliminary 	preliminary 	 JJ	O
,  	,  	 ,	O
results 	results 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
metastatic  	metastatic  	 JJ	B-NP
RCC  	RCC  	 NNP	I-NP
setting 	setting 	 NN	I-NP
,  	,  	 ,	O
recent  	recent  	 JJ	O
advances  	advances  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
molecular  	molecular  	 JJ	B-NP
understanding  	understanding  	 NN	I-NP
of  	of  	 IN	I-NP
oncogenic  	oncogenic  	 JJ	I-NP
pathways  	pathways  	 NNS	I-NP
have  	have  	 VBP	O
led  	led  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
new  	new  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
targeted  	targeted  	 JJ	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
adjuvant  	adjuvant  	 JJ	B-NP
setting 	setting 	 NN	I-NP
.  	.  	 .	O
Neoadjuvant  	Neoadjuvant  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
is  	is  	 VBZ	O
another  	another  	 DT	O
treatment  	treatment  	 NN	B-NP
modality  	modality  	 VBZ	I-NP
currently  	currently  	 RB	O
being  	being  	 VBG	O
evaluated  	evaluated  	 VBN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
early  	early  	 JJ	O
disease  	disease  	 NN	O
and  	and  	 CC	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
metastatic  	metastatic  	 JJ	B-NP
RCC  	RCC  	 NN	I-NP
with  	with  	 IN	O
inoperable  	inoperable  	 JJ	O
primary  	primary  	 JJ	B-NP
tumors 	tumors 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
questions  	questions  	 NNS	O
that  	that  	 WDT	O
remain  	remain  	 VBP	O
unanswered  	unanswered  	 RB	O
include  	include  	 VB	O
activity  	activity  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
in  	in  	 IN	O
early  	early  	 JJ	O
stages  	stages  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
,  	,  	 ,	O
patient  	patient  	 JJ	O
selection 	selection 	 NN	O
,  	,  	 ,	O
optimal  	optimal  	 JJ	B-NP
start  	start  	 NN	I-NP
time  	time  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
adjuvant  	adjuvant  	 JJ	I-NP
treatment 	treatment 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
finally 	finally 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
optimal  	optimal  	 JJ	B-NP
length  	length  	 NN	I-NP
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
